Your browser doesn't support javascript.
loading
Treatment of cushing's syndrome: an Endocrine Society Clinical Practice Guideline
Nieman, L. K; Biller, B. M; Findling, J. W; Murad, M. H; Newell-Price, J; Savage, M. O; Tabarin, A.
Affiliation
  • Nieman, L. K; The Eunice Kennedy Shriver National Institute of Child Health and Human Development. US
  • Biller, B. M; Massachusetts General Hospital. Boston. US
  • Findling, J. W; Medical College of Wisconsin. Milwaukee. US
  • Murad, M. H; Mayo Clinic. Division of Preventive Medicine. Rochester. US
  • Newell-Price, J; University of Sheffield. School of Medicine and Biomedical Science. Department of Human Metabolism. GB
  • Savage, M. O; William Harvey Research Institute. GB
  • Tabarin, A; University of Bordeaux. Centre Hospitalier Universitaire de Bordeaux. Department of Endocrinology. Bordeaux. FR
J. clin. endocrinol. metab ; 100(8)Aug. 2015. ilus, tab
Article in English | BIGG - GRADE guidelines | ID: biblio-964748
Responsible library: BR1.1
ABSTRACT

OBJECTIVE:

The objective is to formulate clinical practice guidelines for treating Cushing's syndrome.

PARTICIPANTS:

Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. EVIDENCE The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines.

CONCLUSIONS:

Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.(AU)
Subject(s)


Full text: Available Collection: Tematic databases Health context: SDG3 - Target 3.8 Achieve universal access to health / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Delivery Arrangements / Endocrine System Diseases / Other Malignant Neoplasms Database: BIGG - GRADE guidelines Main subject: Cushing Syndrome Type of study: Practice guideline Language: English Journal: J. clin. endocrinol. metab Year: 2015 Document type: Article Institution/Affiliation country: Massachusetts General Hospital/US / Mayo Clinic/US / Medical College of Wisconsin/US / The Eunice Kennedy Shriver National Institute of Child Health and Human Development/US / University of Bordeaux/FR / University of Sheffield/GB / William Harvey Research Institute/GB

Full text: Available Collection: Tematic databases Health context: SDG3 - Target 3.8 Achieve universal access to health / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Delivery Arrangements / Endocrine System Diseases / Other Malignant Neoplasms Database: BIGG - GRADE guidelines Main subject: Cushing Syndrome Type of study: Practice guideline Language: English Journal: J. clin. endocrinol. metab Year: 2015 Document type: Article Institution/Affiliation country: Massachusetts General Hospital/US / Mayo Clinic/US / Medical College of Wisconsin/US / The Eunice Kennedy Shriver National Institute of Child Health and Human Development/US / University of Bordeaux/FR / University of Sheffield/GB / William Harvey Research Institute/GB
...